Antitumor activity in primary HGSC cells
Cell-based study · primary cells derived from late-stage HGSC clinical samples [1]
Primary cells derived from late-stage HGSC clinical samples were treated with SNS-032 at 10 pM-10 μM for 72 h, with live cell viability assessed. Antitumor activity was reported across the panel of patient samples and cell lines.
| Endpoint | Reported result | Reference |
|---|---|---|
| live cell viability | Reported result SNS-032 exhibited potent and clinically achievable anti-tumour activity across the panel of patient samples and cell lines | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 pM-10 μM
- Exposure duration
- 72 h
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: SNS-032
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Compounds, cell culture and cell viability assays (S44); Results > Validation of predicted HGSC-specific therapeutics (S113, S115); Fig. 5 legend (S143, S145, S146, S147)
live cell viability: live cell viability; comparator: vehicle control (DMSO) — Methods > Compounds, cell culture and cell viability assays (S44); Results > Validation of predicted HGSC-specific therapeutics (S115)